Table 2.
Distribution of macrolide resistance genes.
| Study | erm(B) | mef(A/E) | only erm(B) | only mef(A/E) | erm(B) + mef(A/E) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Positive | p | Positive | p | Positive | p | Positive | p | Positive | p | |
| n (%) | n (%) | n (%) | n (%) | n (%) | |||||||
| Healthy carrier children’s | 1.000 | 0.022 | 0.953 | 0.026 | 0.892 | ||||||
| Carriage-1a | 84 | 42 (50.0) | 56 (66.7) | 26 (30.9) | 40 (47.6) | 16 (19.1) | |||||
| Carriage-2b | 104 | 52 (50.0) | 52 (50.0) | 33 (31.7) | 33 (31.7) | 19 (18.3) | |||||
| Invasive pneumococcal disease | 0.296 | 0.070 | 0.103 | 0.435 | 0.134 | ||||||
| IPD-1a | 25 | 24 (96.0) | 12 (48.0) | 12 (48.0) | 0 (0.0) | 12 (48.0) | |||||
| IPD-2a | 21 | 20 (95.2) | 17 (80.9) | 4 (19.1) | 1 (4.8) | 16 (76.2) | |||||
| IPD-3b | 67 | 57 (85.1) | 42 (62.7) | 20 (29.8) | 5 (7.5) | 37 (55.2) | |||||
13-valent conjugate vaccine (PCV13) was inserted into the National Immunization Program in 2015.
a
Pre-vaccine studies (Pre PCV13).
b
Post-vaccine studies (Post PCV13).
Statistical significance among carriage studies and among IPD studies.